Search Clinical Trials in the European Union

1-2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
41-60 of 653 trials

Abdominal Aortic Aneurysm: Stem Cell Treatment Study

We are testing whether injecting stem cells into the aneurysm sac is safe and effective for patients undergoing endovascular repair. This study compares outcomes with those from traditional treatment methods.

Abdominal Aortic Aneurysm1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCardiologyInternal MedicineOrthopedics and Traumatology

Roxadustat for Anemia in Children with Chronic Kidney Disease

We are studying a new treatment for anemia in children and adolescents with chronic kidney disease. The trial will evaluate its effectiveness, safety, and how it impacts daily life.

Nephrogenic Anemia1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyNephrology

Systemic Lupus Erythematosus: ESK-001 Treatment Study

We are investigating a new medication, ESK-001, for adults with systemic lupus erythematosus to see if it helps improve disease activity and is safe to use. Participants will receive either ESK-001 or a placebo in this study.

Systemic Lupus Erythematosus1-2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementInternal MedicineRheumatology

Atrial Fibrillation: WOEST-3 Study

We are exploring a new antithrombotic strategy for patients with atrial fibrillation undergoing heart procedures. The goal is to see if this approach reduces bleeding and heart-related risks compared to standard treatment.

Atrial FibrillationAcute Coronary SyndromeChronic Coronary Syndrome1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementCardiologyInternal Medicine

Semaglutide for Weight Loss in Low Responders After Bariatric Surgery

We are studying whether Semaglutide 2.4 mg can help individuals who haven't lost enough weight after bariatric surgery. This trial compares its effects with a placebo to see how it impacts weight loss and overall health.

Obesity1-2 yearsMonitoring phase (IV)>20 visitsStandard MedicinesDiabetologyEndocrinologyInternal Medicine

Atopic Dermatitis: Amlitelimab Injection Study

We are evaluating the long-term safety and effectiveness of amlitelimab injections for individuals aged 12 and older with moderate to severe atopic dermatitis. This study aims to understand how the treatment impacts their symptoms and overall quality of life.

Atopic Dermatitis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteAllergologyDermatology

Hypogammaglobulinemia: XEMBIFY Treatment Study

We are testing whether XEMBIFY, combined with standard treatment, can help prevent infections in patients with hypogammaglobulinemia linked to blood cancers. This study compares its effects to a placebo treatment.

Chronic Lymphocytic Leukaemia1-2 yearsConfirmation phase (III)>20 visitsInvestigational MedicinesCost ReimbursementHematologyInfectious DiseasesOncology

Achondroplasia: TransCon CNP Treatment

We are studying a new weekly injection for children and adolescents with achondroplasia to see if it is safe and helps improve growth. This trial will help us understand the long-term effects of this treatment.

Achondroplasia1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOrthopedics and TraumatologyPediatrics

Guselkumab for Children with Ulcerative Colitis

We are studying whether guselkumab can effectively treat moderately to severely active ulcerative colitis in children. This trial will help us understand its safety and how well it works over time.

Ulcerative Colitis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Polycythemia Vera: Givinostat vs. Hydroxyurea

We are studying a new treatment called Givinostat for patients with high-risk Polycythemia Vera to see if it works better and is safer than the standard medication, hydroxyurea.

Polycythemia Vera1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyInternal Medicine

Advanced Cancers: KFA115 Treatment Study

We are exploring a new drug, KFA115, alone and with pembrolizumab for patients with advanced cancers. The goal is to understand its safety and how well it works.

Epithelial Ovarian CancerThymic CarcinomaMesothelioma1-2 yearsSafety phase (I)Oncology

Prostate Cancer: ADT with Darolutamide

We are studying whether adding darolutamide to standard hormone therapy helps frail men with newly diagnosed metastatic prostate cancer live longer and feel better. This trial compares the new treatment to a placebo to assess its effectiveness.

Metastatic Prostate Cancer1-2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementOncology

Advanced Cutaneous Squamous Cell Carcinoma: INCB099280 Study

We are evaluating a new medication for people with advanced cutaneous squamous cell carcinoma to see how safe it is and if it may help improve their condition.

Recurrent and Metastatic Skin Squamous Cell Carcinoma1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementDermatologyOncology

Acute Myeloid Leukemia: Gilteritinib vs. Midostaurin

We are studying whether gilteritinib works better than midostaurin for patients with AML or MDS with a FLT3 mutation. This trial looks at treatment effectiveness and safety during chemotherapy and maintenance therapy.

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome with Excess Blasts 2 (MDS-EB2)1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Deucravacitinib for Pediatric Plaque Psoriasis

We are studying a new medication for children and teens with moderate to severe plaque psoriasis. The trial will help us understand how well it works and its safety compared to a placebo.

Plaque Psoriasis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteDermatologyPediatrics

Late-onset Pompe Disease: Cipaglucosidase Alfa and Miglustat Study

We are evaluating the safety and effectiveness of a new treatment for children with late-onset Pompe disease. This study aims to understand how well the medications work together and their effects on young patients.

Late-onset Pompe Disease1-2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyHematologyPediatrics

Multiple Sclerosis: BIIB091 Treatment Study

We are studying the safety of BIIB091 alone and with Diroximel Fumarate in adults with relapsing forms of multiple sclerosis. The goal is to see how these treatments affect brain inflammation.

Relapsing Multiple Sclerosis1-2 yearsEfficacy phase (II)16-20 visitsInvestigational MedicinesCost ReimbursementNeurology

Mifepristone as a Weekly Contraceptive

We are studying the effectiveness and safety of a weekly dose of mifepristone for contraception. This trial also looks at how well patients accept this method and any potential effects on liver function.

Oral Contraception1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGynecology and Obstetrics

Neuroendocrine Tumors: SAUNA Trial on Somatostatin Analogues

We are studying whether continuing or stopping somatostatin analogues affects survival and quality of life in patients with neuroendocrine tumors after disease progression. This trial aims to provide insights into the best treatment strategies for these patients.

Neuroendocrine Tumors1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyOncology

Advanced Solid Tumors: INCB099280 Study

We are testing a new medication for patients with advanced solid tumors who have not yet received immune checkpoint inhibitors. The goal is to evaluate its safety and how well it may control the disease.

Advanced Non-Small Cell Lung CancerAdvanced MelanomaUrothelial Carcinoma1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOncology